Metformin and GLP-1 receptor agonists were the most effective non-hormonal options for restoring regular menstrual cycles in adolescents with PCOS, according to this systematic review of 164 studies.
Only 4 Placebo-Controlled Studies FoundDespite screening 265 studies on non-hormonal PCOS treatments in adolescents, only 4 were placebo-controlled — highlighting a major evidence gap even as metformin and GLP-1 agonists show promise
What the researchers found
Among 164 eligible studies from a pool of 265 identified, metformin at dosages of 1500-2550 mg/day emerged as the most effective and cost-efficient non-hormonal treatment for restoring menstrual frequency in overweight adolescents with PCOS, also improving insulin sensitivity. GLP-1 receptor agonists showed effectiveness in menstrual cycle regulation. Supplements including chromium picolinate and myo-inositol also demonstrated some benefits. However, only four placebo-controlled studies were identified, with varying inclusion and exclusion criteria, highlighting the limited evidence base.
Why it matters
PCOS affects up to 10% of women of reproductive age, and irregular periods in adolescence can lead to long-term consequences including hypoestrogenism and bone loss. For teens who cannot take hormonal contraceptives, having effective alternatives is critical. GLP-1 receptor agonists are emerging as a promising peptide-based option that addresses both the metabolic and reproductive aspects of PCOS.
How the study worked
The researchers conducted a systematic literature search across PubMed, Cochrane, Embase, Bio-SISS, and Web of Science covering January 1998 to September 2022. From 265 identified studies, 164 were eligible for evaluation. They assessed non-hormonal pharmacological treatments including metformin, GLP-1 receptor agonists, thiazolidinediones, anti-androgens, and supplements for their effects on menstrual frequency in adolescents with PCOS.
What this study cannot tell us
Only four placebo-controlled studies were identified across the entire search, severely limiting the quality of evidence. Inclusion and exclusion criteria varied widely among studies. Most data came from off-label use of medications. The review focused on adolescents, limiting applicability to adult women with PCOS. Specific GLP-1 agonist dosing and duration data were not detailed.
How to read the evidence
This is a systematic review, which is a strong study design, but the underlying evidence is weak — only four placebo-controlled studies were identified, with heterogeneous criteria. The conclusions about GLP-1 agonist effectiveness are supported by limited evidence.
When this study was published
Published in 2022 with literature through September 2022. The GLP-1 agonist landscape has evolved significantly since, with newer agents like semaglutide and tirzepatide potentially offering improved options.
The bigger picture
GLP-1 receptor agonists are rapidly expanding beyond diabetes and obesity into new therapeutic areas. Their effectiveness in restoring menstrual regularity in PCOS adds another dimension to these peptide drugs' clinical utility. As semaglutide and other GLP-1 agonists become more widely available, they could become important tools for managing PCOS — a condition where metabolic dysfunction and reproductive issues are closely intertwined.
Questions still open
- Which specific GLP-1 receptor agonists are most effective for restoring menstrual regularity in adolescents with PCOS?
- Would combining metformin with a GLP-1 agonist provide greater benefit than either alone for PCOS management?
- Are non-hormonal treatments effective for lean adolescents with PCOS, not just overweight teens?
Common questions
Can GLP-1 drugs help with PCOS symptoms?
What is the best non-hormonal treatment for irregular periods in teens with PCOS?
Read the original research
Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS.
Journal of clinical medicine, 12(1)
Citation
Reiser, Elisabeth; Lanbach, Julia; Böttcher, Bettina; Toth, Bettina. (2022). Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS.. Journal of clinical medicine, 12(1). https://doi.org/10.3390/jcm12010067